DD288094A5 - Verwendung von gamma-interferon zur behandlung von gefaessverengungen - Google Patents

Verwendung von gamma-interferon zur behandlung von gefaessverengungen Download PDF

Info

Publication number: DD288094A5
Authority: DD; German Democratic Republic
Prior art keywords: interferon; gamma; cells; treatment; smooth muscle
Prior art date: 1988-09-30

Application number

DD89333072A

Other languages

German (de)

English (en)

Inventor

Goetan Hansson

Lena Jonasson

Jan Holm

Original Assignee

Hannson Goeran

Lena Jonasson

Jan Holm

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1988-09-30

Filing date

1989-09-28

Publication date

1991-03-21

1989-09-28 Application filed by Hannson Goeran, Lena Jonasson, Jan Holm filed Critical Hannson Goeran

1991-03-21 Publication of DD288094A5 publication Critical patent/DD288094A5/de

Links

108010074328 Interferon-gamma Proteins 0.000 title claims abstract description 87
102000008070 Interferon-gamma Human genes 0.000 title claims abstract description 87
229940044627 gamma-interferon Drugs 0.000 title claims abstract description 87
206010057469 Vascular stenosis Diseases 0.000 claims abstract description 17
206010060965 Arterial stenosis Diseases 0.000 claims abstract description 12
238000002399 angioplasty Methods 0.000 claims abstract description 12
238000007631 vascular surgery Methods 0.000 claims abstract description 11
239000000825 pharmaceutical preparation Substances 0.000 claims abstract description 9
208000037803 restenosis Diseases 0.000 claims abstract description 9
208000031104 Arterial Occlusive disease Diseases 0.000 claims abstract description 4
208000021328 arterial occlusion Diseases 0.000 claims abstract description 4
238000000034 method Methods 0.000 claims description 22
238000002360 preparation method Methods 0.000 claims description 8
102000014150 Interferons Human genes 0.000 claims description 7
108010050904 Interferons Proteins 0.000 claims description 7
229940079322 interferon Drugs 0.000 claims description 5
230000001225 therapeutic effect Effects 0.000 claims description 4
206010020718 hyperplasia Diseases 0.000 abstract description 11
208000031481 Pathologic Constriction Diseases 0.000 abstract description 3
238000004519 manufacturing process Methods 0.000 abstract description 3
230000036262 stenosis Effects 0.000 abstract description 3
208000037804 stenosis Diseases 0.000 abstract description 3
210000004027 cell Anatomy 0.000 description 79
210000000329 smooth muscle myocyte Anatomy 0.000 description 52
230000014509 gene expression Effects 0.000 description 41
229940104230 thymidine Drugs 0.000 description 26
239000000427 antigen Substances 0.000 description 25
108091007433 antigens Proteins 0.000 description 25
102000036639 antigens Human genes 0.000 description 25
241000700159 Rattus Species 0.000 description 21
230000003902 lesion Effects 0.000 description 18
210000001744 T-lymphocyte Anatomy 0.000 description 16
230000000694 effects Effects 0.000 description 14
230000035755 proliferation Effects 0.000 description 14
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 12
230000012010 growth Effects 0.000 description 12
208000027418 Wounds and injury Diseases 0.000 description 10
230000006378 damage Effects 0.000 description 10
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 10
230000005764 inhibitory process Effects 0.000 description 10
239000002953 phosphate buffered saline Substances 0.000 description 10
238000004458 analytical method Methods 0.000 description 9
230000022131 cell cycle Effects 0.000 description 9
208000014674 injury Diseases 0.000 description 9
210000002966 serum Anatomy 0.000 description 9
241001465754 Metazoa Species 0.000 description 7
238000002474 experimental method Methods 0.000 description 7
230000004663 cell proliferation Effects 0.000 description 6
210000002460 smooth muscle Anatomy 0.000 description 6
201000001320 Atherosclerosis Diseases 0.000 description 5
108010058597 HLA-DR Antigens Proteins 0.000 description 5
102000006354 HLA-DR Antigens Human genes 0.000 description 5
238000002835 absorbance Methods 0.000 description 5
210000002950 fibroblast Anatomy 0.000 description 5
230000003204 osmotic effect Effects 0.000 description 5
230000008458 response to injury Effects 0.000 description 5
238000001356 surgical procedure Methods 0.000 description 5
206010003210 Arteriosclerosis Diseases 0.000 description 4
208000037260 Atherosclerotic Plaque Diseases 0.000 description 4
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
108091003079 Bovine Serum Albumin Proteins 0.000 description 4
230000006820 DNA synthesis Effects 0.000 description 4
101000817629 Homo sapiens Dymeclin Proteins 0.000 description 4
102000003978 Tissue Plasminogen Activator Human genes 0.000 description 4
108090000373 Tissue Plasminogen Activator Proteins 0.000 description 4
208000011775 arteriosclerosis disease Diseases 0.000 description 4
210000001367 artery Anatomy 0.000 description 4
210000001715 carotid artery Anatomy 0.000 description 4
210000004351 coronary vessel Anatomy 0.000 description 4
210000002889 endothelial cell Anatomy 0.000 description 4
230000009036 growth inhibition Effects 0.000 description 4
239000002609 medium Substances 0.000 description 4
230000005012 migration Effects 0.000 description 4
238000013508 migration Methods 0.000 description 4
238000002560 therapeutic procedure Methods 0.000 description 4
229960000187 tissue plasminogen activator Drugs 0.000 description 4
210000004509 vascular smooth muscle cell Anatomy 0.000 description 4
108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 3
102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 3
241000699666 Mus <mouse, genus> Species 0.000 description 3
208000034827 Neointima Diseases 0.000 description 3
108010093965 Polymyxin B Proteins 0.000 description 3
BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
206010072810 Vascular wall hypertrophy Diseases 0.000 description 3
238000011161 development Methods 0.000 description 3
239000002158 endotoxin Substances 0.000 description 3
239000012894 fetal calf serum Substances 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
239000003112 inhibitor Substances 0.000 description 3
230000002401 inhibitory effect Effects 0.000 description 3
210000002540 macrophage Anatomy 0.000 description 3
208000010125 myocardial infarction Diseases 0.000 description 3
239000008363 phosphate buffer Substances 0.000 description 3
229920000024 polymyxin B Polymers 0.000 description 3
229960005266 polymyxin b Drugs 0.000 description 3
230000002062 proliferating effect Effects 0.000 description 3
229910052709 silver Inorganic materials 0.000 description 3
239000004332 silver Substances 0.000 description 3
238000007619 statistical method Methods 0.000 description 3
208000024891 symptom Diseases 0.000 description 3
230000001360 synchronised effect Effects 0.000 description 3
238000002054 transplantation Methods 0.000 description 3
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
108020004414 DNA Proteins 0.000 description 2
238000002965 ELISA Methods 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
108010062347 HLA-DQ Antigens Proteins 0.000 description 2
WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
229920001213 Polysorbate 20 Polymers 0.000 description 2
108020004511 Recombinant DNA Proteins 0.000 description 2
238000000692 Student's t-test Methods 0.000 description 2
230000003143 atherosclerotic effect Effects 0.000 description 2
238000000376 autoradiography Methods 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
210000001168 carotid artery common Anatomy 0.000 description 2
238000004113 cell culture Methods 0.000 description 2
238000011109 contamination Methods 0.000 description 2
230000007812 deficiency Effects 0.000 description 2
210000000497 foam cell Anatomy 0.000 description 2
239000001963 growth medium Substances 0.000 description 2
229960002897 heparin Drugs 0.000 description 2
229920000669 heparin Polymers 0.000 description 2
229940027941 immunoglobulin g Drugs 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
230000006698 induction Effects 0.000 description 2
230000008595 infiltration Effects 0.000 description 2
238000001764 infiltration Methods 0.000 description 2
238000001802 infusion Methods 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
229940047124 interferons Drugs 0.000 description 2
230000000302 ischemic effect Effects 0.000 description 2
210000000265 leukocyte Anatomy 0.000 description 2
239000007788 liquid Substances 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
239000000203 mixture Substances 0.000 description 2
210000000663 muscle cell Anatomy 0.000 description 2
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
229920000136 polysorbate Polymers 0.000 description 2
238000011160 research Methods 0.000 description 2
238000003345 scintillation counting Methods 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
238000013222 sprague-dawley male rat Methods 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
239000000126 substance Substances 0.000 description 2
239000000758 substrate Substances 0.000 description 2
238000011287 therapeutic dose Methods 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
NAQWICRLNQSPPW-UHFFFAOYSA-N 1,2,3,4-tetrachloronaphthalene Chemical compound C1=CC=CC2=C(Cl)C(Cl)=C(Cl)C(Cl)=C21 NAQWICRLNQSPPW-UHFFFAOYSA-N 0.000 description 1
XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
HKJKONMZMPUGHJ-UHFFFAOYSA-N 4-amino-5-hydroxy-3-[(4-nitrophenyl)diazenyl]-6-phenyldiazenylnaphthalene-2,7-disulfonic acid Chemical compound OS(=O)(=O)C1=CC2=CC(S(O)(=O)=O)=C(N=NC=3C=CC=CC=3)C(O)=C2C(N)=C1N=NC1=CC=C([N+]([O-])=O)C=C1 HKJKONMZMPUGHJ-UHFFFAOYSA-N 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
206010002383 Angina Pectoris Diseases 0.000 description 1
206010003162 Arterial injury Diseases 0.000 description 1
241000283707 Capra Species 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
241000282412 Homo Species 0.000 description 1
101000599940 Homo sapiens Interferon gamma Proteins 0.000 description 1
208000035150 Hypercholesterolemia Diseases 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
102100025323 Integrin alpha-1 Human genes 0.000 description 1
108010041341 Integrin alpha1 Proteins 0.000 description 1
108010055795 Integrin alpha1beta1 Proteins 0.000 description 1
102000006992 Interferon-alpha Human genes 0.000 description 1
108010047761 Interferon-alpha Proteins 0.000 description 1
102000003996 Interferon-beta Human genes 0.000 description 1
108090000467 Interferon-beta Proteins 0.000 description 1
102000010789 Interleukin-2 Receptors Human genes 0.000 description 1
108010038453 Interleukin-2 Receptors Proteins 0.000 description 1
102000004083 Lymphotoxin-alpha Human genes 0.000 description 1
108090000542 Lymphotoxin-alpha Proteins 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
241001529936 Murinae Species 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
208000002193 Pain Diseases 0.000 description 1
229930040373 Paraformaldehyde Natural products 0.000 description 1
108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
208000007536 Thrombosis Diseases 0.000 description 1
108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
208000024248 Vascular System injury Diseases 0.000 description 1
208000012339 Vascular injury Diseases 0.000 description 1
230000035508 accumulation Effects 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
239000008351 acetate buffer Substances 0.000 description 1
230000004913 activation Effects 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
125000000539 amino acid group Chemical group 0.000 description 1
150000001413 amino acids Chemical group 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000002022 anti-cellular effect Effects 0.000 description 1
230000001028 anti-proliverative effect Effects 0.000 description 1
230000000840 anti-viral effect Effects 0.000 description 1
210000000709 aorta Anatomy 0.000 description 1
239000013011 aqueous formulation Substances 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
238000000211 autoradiogram Methods 0.000 description 1
210000003323 beak Anatomy 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
210000004899 c-terminal region Anatomy 0.000 description 1
244000309466 calf Species 0.000 description 1
230000000747 cardiac effect Effects 0.000 description 1
238000007675 cardiac surgery Methods 0.000 description 1
238000013172 carotid endarterectomy Methods 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
238000003115 checkerboard titration Methods 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
238000010367 cloning Methods 0.000 description 1
239000002131 composite material Substances 0.000 description 1
230000001143 conditioned effect Effects 0.000 description 1
238000007887 coronary angioplasty Methods 0.000 description 1
208000029078 coronary artery disease Diseases 0.000 description 1
238000012937 correction Methods 0.000 description 1
210000004748 cultured cell Anatomy 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
230000029087 digestion Effects 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
239000012895 dilution Substances 0.000 description 1
238000010790 dilution Methods 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
238000006073 displacement reaction Methods 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
239000003814 drug Substances 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
230000003511 endothelial effect Effects 0.000 description 1
210000003989 endothelium vascular Anatomy 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
230000001605 fetal effect Effects 0.000 description 1
238000009472 formulation Methods 0.000 description 1
230000006870 function Effects 0.000 description 1
230000004927 fusion Effects 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
239000003966 growth inhibitor Substances 0.000 description 1
230000035876 healing Effects 0.000 description 1
208000013210 hematogenous Diseases 0.000 description 1
230000002055 immunohistochemical effect Effects 0.000 description 1
238000011532 immunohistochemical staining Methods 0.000 description 1
238000003364 immunohistochemistry Methods 0.000 description 1
230000001976 improved effect Effects 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
210000004969 inflammatory cell Anatomy 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
238000011835 investigation Methods 0.000 description 1
230000002147 killing effect Effects 0.000 description 1
230000002045 lasting effect Effects 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
210000003141 lower extremity Anatomy 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
210000005075 mammary gland Anatomy 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
239000000463 material Substances 0.000 description 1
231100000682 maximum tolerated dose Toxicity 0.000 description 1
210000003593 megakaryocyte Anatomy 0.000 description 1
210000001616 monocyte Anatomy 0.000 description 1
210000004980 monocyte derived macrophage Anatomy 0.000 description 1
238000013425 morphometry Methods 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
210000002464 muscle smooth vascular Anatomy 0.000 description 1
230000035407 negative regulation of cell proliferation Effects 0.000 description 1
230000003076 paracrine Effects 0.000 description 1
229920002866 paraformaldehyde Polymers 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
229940056360 penicillin g Drugs 0.000 description 1
230000010412 perfusion Effects 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
229940068977 polysorbate 20 Drugs 0.000 description 1
230000002980 postoperative effect Effects 0.000 description 1
230000001323 posttranslational effect Effects 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
230000008569 process Effects 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
238000012545 processing Methods 0.000 description 1
239000000047 product Substances 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
230000001007 puffing effect Effects 0.000 description 1
238000000746 purification Methods 0.000 description 1
230000005855 radiation Effects 0.000 description 1
108700038606 rat Smooth muscle Proteins 0.000 description 1
238000002278 reconstructive surgery Methods 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
230000014493 regulation of gene expression Effects 0.000 description 1
230000026267 regulation of growth Effects 0.000 description 1
230000004044 response Effects 0.000 description 1
238000005070 sampling Methods 0.000 description 1
238000002741 site-directed mutagenesis Methods 0.000 description 1
230000000391 smoking effect Effects 0.000 description 1
239000012064 sodium phosphate buffer Substances 0.000 description 1
238000005063 solubilization Methods 0.000 description 1
230000007928 solubilization Effects 0.000 description 1
239000000243 solution Substances 0.000 description 1
241000894007 species Species 0.000 description 1
238000012453 sprague-dawley rat model Methods 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000013589 supplement Substances 0.000 description 1
238000011477 surgical intervention Methods 0.000 description 1
238000012360 testing method Methods 0.000 description 1
230000005919 time-dependent effect Effects 0.000 description 1
230000007704 transition Effects 0.000 description 1
YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
230000001960 triggered effect Effects 0.000 description 1
102000003390 tumor necrosis factor Human genes 0.000 description 1
230000002792 vascular Effects 0.000 description 1
210000005166 vasculature Anatomy 0.000 description 1
239000008215 water for injection Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/217—IFN-gamma
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Zoology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Chemical Kinetics & Catalysis (AREA)
Heart & Thoracic Surgery (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Cardiology (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Radiation-Therapy Devices (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

DD89333072A 1988-09-30 1989-09-28 Verwendung von gamma-interferon zur behandlung von gefaessverengungen DD288094A5 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
SE8803472A SE462364B (sv)	1988-09-30	1988-09-30	Anvaendning av gamma-interferon foer beredning av ett preparat foer behandling av vaskulaer stenos

Publications (1)

Publication Number	Publication Date
DD288094A5 true DD288094A5 (de)	1991-03-21

Family

ID=20373494

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DD89333072A DD288094A5 (de)	1988-09-30	1989-09-28	Verwendung von gamma-interferon zur behandlung von gefaessverengungen

Country Status (18)

Country	Link
US (1)	US5208019A (da)
EP (1)	EP0367735B1 (da)
JP (1)	JP2895896B2 (da)
KR (1)	KR0137017B1 (da)
AT (1)	ATE86869T1 (da)
AU (1)	AU623181B2 (da)
CA (1)	CA1338722C (da)
DD (1)	DD288094A5 (da)
DE (1)	DE68905438T2 (da)
DK (1)	DK174523B1 (da)
HU (1)	HU206988B (da)
IE (1)	IE63874B1 (da)
IL (1)	IL91796A (da)
NZ (1)	NZ230816A (da)
PH (1)	PH26293A (da)
PT (1)	PT91863B (da)
SE (1)	SE462364B (da)
WO (1)	WO1990003189A1 (da)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6515009B1 (en)	1991-09-27	2003-02-04	Neorx Corporation	Therapeutic inhibitor of vascular smooth muscle cells
US5811447A (en)	1993-01-28	1998-09-22	Neorx Corporation	Therapeutic inhibitor of vascular smooth muscle cells
WO1993015609A1 (en) *	1992-02-05	1993-08-19	Thomas Jefferson University	Interferon gene therapy for the treatment of vascular disorders
US6251920B1 (en)	1993-05-13	2001-06-26	Neorx Corporation	Prevention and treatment of cardiovascular pathologies
US6395494B1 (en) *	1993-05-13	2002-05-28	Neorx Corporation	Method to determine TGF-β
US6306421B1 (en)	1992-09-25	2001-10-23	Neorx Corporation	Therapeutic inhibitor of vascular smooth muscle cells
US5770609A (en) *	1993-01-28	1998-06-23	Neorx Corporation	Prevention and treatment of cardiovascular pathologies
US5957972A (en) *	1992-09-29	1999-09-28	Arizona Board Of Regents On Behalf Of The University Of Arizona	Implants possessing a surface of endothelial cells genetically-modified to inhibit intimal thickening
BR9405707A (pt) *	1993-01-07	1996-08-06	Univ Jefferson	Inibiçao anti-sentido de c-myc para modular a proliferaçao de células de músculo liso
US5595722A (en) *	1993-01-28	1997-01-21	Neorx Corporation	Method for identifying an agent which increases TGF-beta levels
US6491938B2 (en)	1993-05-13	2002-12-10	Neorx Corporation	Therapeutic inhibitor of vascular smooth muscle cells
US5981568A (en)	1993-01-28	1999-11-09	Neorx Corporation	Therapeutic inhibitor of vascular smooth muscle cells
US6663881B2 (en)	1993-01-28	2003-12-16	Neorx Corporation	Therapeutic inhibitor of vascular smooth muscle cells
DE69435137D1 (de) *	1993-05-13	2008-10-16	Poniard Pharmaceuticals Inc	Prävention und behandlung von pathologien, die mit einer abnormalen proliferationglatter muskelzellen verbunden sind
WO1996040098A2 (en)	1995-06-07	1996-12-19	Neorx Corporation	Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
US6133242A (en) *	1993-10-15	2000-10-17	Thomas Jefferson Univerisity	Inhibition of extracellular matrix synthesis by antisense compounds directed to nuclear proto-oncogenes
US6323184B1 (en)	1993-10-15	2001-11-27	Thomas Jefferson University	Arteriovenous and venous graft treatments: methods and compositions
US5449679A (en) *	1994-07-29	1995-09-12	Leonard; Robert J.	Process and products for reducing biological fluid levels of a lipid soluble waste
US5665591A (en) *	1994-12-06	1997-09-09	Trustees Of Boston University	Regulation of smooth muscle cell proliferation
US7611533B2 (en) *	1995-06-07	2009-11-03	Cook Incorporated	Coated implantable medical device
CA2210622A1 (en) *	1995-11-17	1997-05-29	Toray Industries, Inc.	An agent protecting endothelial cells
US5681558A (en) *	1995-11-30	1997-10-28	Berlex Laboratories, Inc.	Method of using beta-interferons to treat restenosis
BR9909422A (pt)	1998-04-02	2001-09-11	Genentech Inc	Método para tratamento de hipertrofia cardìaca, método para preparação de composição farmacêutica para o tratamento de hipertrofia cardìaca e seu produto farmacêutico
US7524826B2 (en) *	2000-04-14	2009-04-28	Mcmaster University And Hamilton Health Sciences Corporation	Method of inhibiting the generation of active thrombin on the surface of a cell within an atherosclerotic plaque
US6613083B2 (en)	2001-05-02	2003-09-02	Eckhard Alt	Stent device and method
AU2002310922A1 (en) *	2001-05-04	2002-11-18	Institute Of Molecular And Cell Biology	Interferons in the treatment of ischemia
BRPI0507169A (pt)	2004-02-02	2007-06-26	Ambrx Inc	polipeptìdeos do hormÈnio de crescimento humano modificados e seu usos

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE11014T1 (de) *	1981-07-14	1985-01-15	Efamol Limited	Pharmazeutische und diaetetische zusammensetzung zur erhoehung der serie-l-pg-produktion.
US5096705A (en) *	1981-10-19	1992-03-17	Genentech, Inc.	Human immune interferon
US4454115A (en) *	1981-10-23	1984-06-12	Wisconsin Alumni Research Foundation	Method of reducing the level of low density lipoproteins in the serum of a patient
US4483849A (en) *	1983-01-07	1984-11-20	Carter William A	Stabilization and purification of interferon with propylene glycol, resulting in a non-toxic product
JPS6069037A (ja) *	1983-09-26	1985-04-19	Sunstar Inc	エリテマト−デス治療用外用剤
US4680175A (en) *	1984-02-07	1987-07-14	Interferon Sciences, Inc.	Interferon administration vehicles
US4605555A (en) *	1984-09-20	1986-08-12	Sun Star Kabushiki Kaisha	Composition and method for treating keratosic disorder of skin and mucosa
US4946674A (en) *	1984-10-05	1990-08-07	Bioferon Biochemische Substanzen Gmbh & Co.	Process for treatment of rheumatic diseases
IL78444A (en) *	1986-04-08	1992-05-25	Yeda Res & Dev	Human gamma interferon-specific receptor protein,antibody against said protein,and compositions containing said protein and antibody
US5026544A (en) *	1988-02-16	1991-06-25	Board Of Reagents, The University Of Texas System	Methods and compositions for inhibiting the growth of neoplastic cells

1988
- 1988-09-30 SE SE8803472A patent/SE462364B/sv not_active IP Right Cessation
1989
- 1989-09-27 HU HU895542A patent/HU206988B/hu not_active IP Right Cessation
- 1989-09-27 KR KR1019900701144A patent/KR0137017B1/ko not_active Expired - Lifetime
- 1989-09-27 DE DE89850317T patent/DE68905438T2/de not_active Expired - Lifetime
- 1989-09-27 EP EP89850317A patent/EP0367735B1/en not_active Expired - Lifetime
- 1989-09-27 WO PCT/SE1989/000520 patent/WO1990003189A1/en not_active Ceased
- 1989-09-27 JP JP1510051A patent/JP2895896B2/ja not_active Expired - Lifetime
- 1989-09-27 US US07/671,786 patent/US5208019A/en not_active Expired - Lifetime
- 1989-09-27 AU AU43051/89A patent/AU623181B2/en not_active Expired
- 1989-09-27 IL IL9179689A patent/IL91796A/en not_active IP Right Cessation
- 1989-09-27 AT AT89850317T patent/ATE86869T1/de not_active IP Right Cessation
- 1989-09-28 DD DD89333072A patent/DD288094A5/de unknown
- 1989-09-28 NZ NZ230816A patent/NZ230816A/en unknown
- 1989-09-29 IE IE312389A patent/IE63874B1/en not_active IP Right Cessation
- 1989-09-29 PT PT91863A patent/PT91863B/pt not_active IP Right Cessation
- 1989-09-29 PH PH39308A patent/PH26293A/en unknown
- 1989-09-29 CA CA000614859A patent/CA1338722C/en not_active Expired - Lifetime
1991
- 1991-03-27 DK DK199100562A patent/DK174523B1/da not_active IP Right Cessation

Also Published As

Publication number	Publication date
IE63874B1 (en)	1995-06-14
PH26293A (en)	1992-04-10
IE893123L (en)	1990-03-30
DK56291D0 (da)	1991-03-27
AU4305189A (en)	1990-04-18
SE8803472D0 (sv)	1988-09-30
EP0367735B1 (en)	1993-03-17
WO1990003189A1 (en)	1990-04-05
ATE86869T1 (de)	1993-04-15
DK56291A (da)	1991-05-24
NZ230816A (en)	1997-06-24
DK174523B1 (da)	2003-05-12
HUT57063A (en)	1991-11-28
DE68905438D1 (de)	1993-04-22
PT91863B (pt)	1995-05-31
HU206988B (en)	1993-03-01
SE462364B (sv)	1990-06-18
PT91863A (pt)	1990-03-30
EP0367735A1 (en)	1990-05-09
AU623181B2 (en)	1992-05-07
JP2895896B2 (ja)	1999-05-24
IL91796A (en)	1994-10-07
IL91796A0 (en)	1990-06-10
US5208019A (en)	1993-05-04
JPH04500966A (ja)	1992-02-20
KR900701308A (ko)	1990-12-01
CA1338722C (en)	1996-11-19
HU895542D0 (en)	1991-10-28
DE68905438T2 (de)	1993-09-30
KR0137017B1 (ko)	1998-04-25

Legal Events

Date	Code	Title	Description
1994-12-08	RPI	Change in the person, name or address of the patentee (searches according to art. 11 and 12 extension act)
1994-12-22	RPV	Change in the person, the name or the address of the representative (searches according to art. 11 and 12 extension act)
2004-04-28	ASS	Change of applicant or owner	Owner name: GENENTECH, INC., SOUTH SAN FRANCISCO, CA 94080 Effective date: 19941010 Owner name: JONASSON, LENA Effective date: 19941010 Owner name: HOLM, JAN Effective date: 19941010
2004-04-28	IF04	In force in the year 2004	Expiry date: 20090929

Publication	Publication Date	Title
DE68905438T2 (de)	1993-09-30	Verwendung von Interferon-gamma in pharmazeutischen Zubereitungen zur Behandlung von Gefässstenose.
DE3855970T2 (de)	1998-01-29	Verwendung von Amylin oder CGRP zur Behandlung des Diabetes mellitus
DE69432179T2 (de)	2003-07-24	Eine formulierung des gerinnungsfaktors viii
DE69130289T2 (de)	1999-06-02	Therapeutische verwendung von actin-bindenden verbindungen
DE69533069T2 (de)	2005-05-12	Zusammensetzung zur hemmung von innerer hyperplasie unter verwendung von pdgf antagonisten und heparin
DE69503120T3 (de)	2003-08-14	Zusammensetzungen aus einer thrombolytisch wirkende substanz und antikoagulantien, und ihre verwendungen
DE3887875T2 (de)	1994-08-18	Verfahren zur vorbeugung einer von blutplättchen abhängigen gefässthrombose.
DE69123960T2 (de)	1997-05-07	Behandlung von entzündungen
DE69713485T2 (de)	2003-01-30	Medikamente für die Behandlung oder Vorbeugung von Thrombocytopenie
DE69429816T2 (de)	2002-09-19	C1-Esterasehemmer zur Verringerung von Myokardschäden bei akutem Herzinfarkt
DE60029340T2 (de)	2007-07-19	Pharmazeutische zusammenstellungen enthaltend einen p2t rezeptor antagonist und melagatran
DE60037816T2 (de)	2009-01-08	Pharmazeutische formulierung enthaltend megalatran und dessen pro-pharmaka
LU84546A1 (de)	1983-09-08	Verwendung von peptiden als medikamente
DE69024053T2 (de)	1996-07-04	Behandlung zur ermässigung von ödem und muskelschäden.
EP0586909A2 (de)	1994-03-16	Verwendung von C1-Inaktivator zur Herstellung eines Arzneimittels zur Prophylaxe und Therapie des Capillary Leak Syndroms und Kreislaufschocks
DE69232596T2 (de)	2003-01-09	Inhibitor von nebenwirkungen zur krebstherapy
DE60301862T2 (de)	2006-07-20	Kombinationsbehandlung bei akutem myokardinfarkt
EP0363671A2 (de)	1990-04-18	Verwendung von ACE-Inhibitoren gegen Neointimabildung nach Gefässverletzung
DE69726281T2 (de)	2004-08-26	Hemmstoff für die gefässneubildung, der den gewebefaktor-inhibitor (tfpi) enthält
DE60128399T2 (de)	2008-01-10	Verwendung von thrombomodulinanaloga zur regenerierung von rückenmarkverletzungen
DE60130906T2 (de)	2008-07-17	Synergistische wirkungen von hgf und antibakterieller behandlung
EP0331014A2 (de)	1989-09-06	Verwendung von ACE-Inhibitoren für die Diabetesprophylaxe
DE69109676T2 (de)	1996-02-08	Verminderung von kardiovaskulären gefässverschlüssen mit ascorbat und hemmstoffen der bindung von lipoprotein (a).
DE69836830T2 (de)	2007-10-11	Verwendung von proteinen der midkine-familie in der behandlung von ischämischen krankheiten
DE69317343T2 (de)	1998-10-08	Verwendung eines direkten Inhibitors von Thrombin zur Herstellung eines Arzneimittels mit thrombolytischer Aktivität